AIM AIM ImmunoTech

AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones

OCALA, Fla., Jan. 15, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday, January 21, 2021 to discuss of the treatment of subjects with COVID-19-induced chronic fatigue-like symptoms in the amended AMP-511 trial, recent accomplishments and upcoming milestones.

Investors and other interested parties are invited to submit questions to management prior to the call's start via email to . Management respectfully requests that questions be non-compound, direct and addressing single subjects.

The conference call will be available on the Company’s website at , or via telephone by dialing toll free 877-407-8031 for U.S. callers, or for international callers.

For those unable to participate at that time, a replay of the call will be archived on the Company’s website or can be accessed by dialing 877-481-4010 for U.S. callers, or for international callers and entering the pass code 39447. The replay will be available for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Contacts:

Crescendo Communications, LLC

Phone: 212-671-1021

Email: 

AIM ImmunoTech Inc.

Phone: 800-778-4042

Email: 



EN
15/01/2021

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Extension of Subscription Period of its Previ...

AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Tim...

23h / 13m 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Tri...

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Ev...

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that of AIM, will participate in a  on Thursday, February 19, 2026, at 4:00 PM ET. Equels will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing  in col...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech Announces Commencement of Rights Offering OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”).  Pursuant to the Rights Offering, the Company is distributing to all holders of record of ...

February 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch